[Follow-up of immunological parameters and therapy of systemic lupus erythematosus].
In a longitudinal study of a female patient with systemic lupus erythematosus, we determined numbers of T-lymphocytes and subpopulations (OKT4+- and OKT8+-lymphocytes), B-lymphocytes, production of anti-double-stranded DNA antibody (anti-ds-DNA-Ab), and we investigated the effects of corticosteroids and cyclophosphamide on these parameters and clinical disease activity. The results demonstrate that an increase of OKT4+-T-lymphocytes/OKT8+-T-lymphocytes ratio apparently augments B-lymphocyte numbers resulting in anti-ds-DNA-Ab production. Whereas steroids exerted limited, possibly dose-dependent effects on this sequence, cyclophosphamide seemed to cause normalization of OKT4+/OKT8+ ratio, precipitous drop of anti-ds-DNA-Ab titers, and dramatic clinical improvement.
D000305:Adrenal Cortex Hormones / Q000494:pharmacology; D000974:Antibodies, Antinuclear / Q000032:analysis; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D003520:Cyclophosphamide / Q000494:pharmacology; D004247:DNA / Q000276:immunology; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007958:Leukocyte Count; D008137:Longitudinal Studies; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology*; D008875:Middle Aged; D011239:Prednisolone / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
D000305:Adrenal Cortex Hormones; D000974:Antibodies, Antinuclear; D003520:Cyclophosphamide; D004247:DNA; D011239:Prednisolone
Verlaufskontrolle immunologischer Parameter und Therapie beim systemischen Lupus erythematodes.